Sai Life Sciences enters Q1 FY27 with a robust pipeline of 45 late-phase molecules, aiming to sustain its growth momentum amidst a shifting global supply chain landscape. Investors will be focused on whether the company can maintain its 28-30% EBITDA margin target while scaling up significant capex for capacity expansion.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 602 Cr |
| Previous quarter PAT | Rs. 104 Cr |
| Previous quarter EBITDA margin | 31% |
| Market cap | Rs. 27918.9 Cr |
| CMP | Rs. 1315.1 |
The Board of Directors is scheduled to meet on August 06, 2026, to approve the unaudited standalone and consolidated financial results for Q1 FY27.
An earnings conference call is scheduled for August 07, 2026, from 4:00 PM to 5:00 PM IST, featuring MD & CEO Mr. Krishna Kanumuri and Director & CFO Mr. Siva Chittor.
Sai Life Sciences is expected to deliver YoY revenue growth within its 15-20% CAGR corridor, significantly aided by a 12-14% YoY depreciation in the rupee against the USD during the quarter. While the Q1 FY26 base of Rs. 496 Cr provides an easy YoY comparison, the company's ability to maintain its 28-30% EBITDA margin band will be tested by the ongoing investment in scientific talent and the high-growth capex cycle. Management has reaffirmed a long-term commitment to this margin range, balancing growth investments against the need to compete with large-scale Chinese CDMO players. With a near-zero net debt position entering the quarter, the company is well-positioned to fund its Rs. 1,100-1,300 Cr FY27 capex plan, which includes the commissioning of a 225 KL block at the Bidar facility by Q2 FY27. The upcoming call will likely clarify the CRO segment's performance, given that biotech funding recovery is not anticipated for another 18-24 months.
Performance vs Guidance Tracking: Tracking progress against the company's stated long-term financial and operational goals.
Capacity commissioning status: Updates on key infrastructure projects essential for future growth.
Operating metric trajectory: Monitoring the balance between CDMO and CRO segment performance.
Risks and headwinds to monitor: External factors impacting quarterly operations and margin profile.
In Q4 FY26, the company reported revenue of Rs. 602 Cr, a 3.8% increase YoY, and PAT of Rs. 104 Cr, up 18.2% YoY. Management noted that the quarterly growth was moderated by lumpy revenue recognition linked to customer purchase order timing.
Management aims to sustain a steady-state EBITDA margin in the 28-30% range. They have indicated that while they are not exhausting all margin levers, they are balancing growth investments against margin optimization to remain competitive against large-scale Chinese CDMO players.
The company is currently executing a 450 KL expansion at its Bidar site to reach a total capacity of 1,150 KL by the end of FY27. The first 225 KL block is scheduled for commissioning in Q2 FY27.
Yes, the company's revenue CAGR guidance is 15-20% over 3-5 years, and FY26 revenue grew by 29.3% YoY, exceeding the upper end of this range. Management has clarified that current growth is broad-based and not merely a result of pulling forward future orders.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now